Drug Hunter
APRIL 20, 2023
We asked the global drug discovery community to nominate and vote on their favorite molecule from 2022, and the results are in. The 2022 winner, with the most overall votes across the ten finalist molecules , is BMS’ oral, deuterated allosteric TYK2 inhibitor, deucravacitinib, the first new treatment for plaque psoriasis in nearly a decade. Here, we highlight what makes deucravacitinib so impressive to the drug discovery community.
Drug Discovery Today
APRIL 20, 2023
Global integrated drug discovery company, Sygnature Discovery and global healthcare group Daewoong Pharmaceutical, have entered into a research collaboration agreement to accelerate the discovery of a novel small molecule to target autoimmune disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Chemical Biology and Drug Design
APRIL 20, 2023
The design of in silico and in vitro study. Abstract Colorectal cancer (CRC) is the second most common cancer in women and the third most common in men worldwide. Impaired cell cycle regulation leads to many cancers and is also approved in CRC. Therefore, cell cycle regulation is a critical therapeutic target for CRC. Furthermore, miRNAs have been discovered as regulators in a variety of cancer-related pathways.
Antidote
APRIL 17, 2023
Homocystinuria, an inherited disorder, is a rare metabolic condition that impacts 1 in 335,000 people worldwide and is present from birth. Often abbreviated as HCU or HCY, homocystinuria is a genetic disorder that inhibits the body from processing certain amino acids found in proteins, causing a harmful buildup of homocysteine and methionine.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
APRIL 19, 2023
This article was originally published by Jiayi Chen, Zhifeng Zhao, Xinyu Wang and Jingjun Huang in Drug Repurposing – Advances, Scopes and Opportunities in Drug Discovery and is republished here… The post Utilizing 505(b)(2) Regulatory Pathway for New Drug Applications: An Overview on the Advanced Formulation Approach and Challenges appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
APRIL 17, 2023
A retrospective chart review interim analysis demonstrated that cefiderocol achieved clinical cure in 65% and 60% of patients with Pseudomonas aeruginosa and Acinetobacter baumannii respectively, the majority of whom were severely ill with comorbidities.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Channels
APRIL 18, 2023
Like it or not, the Centers for Medicare & Medicaid Services (CMS) is barreling ahead with its implementation of the Inflation Reduction Act of 2022 (IRA). Last Friday was the last day to submit comments on CMS's initial guidance on the drug price negotiation program. The IRA will alter many crucial aspects of the Medicare program and the overall drug channel.
FDA Law Blog: Biosimilars
APRIL 19, 2023
By Deborah L. Livornese — Last week FDA checked off another item on its to-do list for implementing the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) OTC monograph reform provisions. As provided in the OMUFA Performance Goals letter , FDA issued draft guidance on the content and format of submissions. The draft guidance for industry entitled Over-the-Counter Monograph Order Requests (OMORs): Format and Content , outlines the information (content) and the form of and manner in
Drug Discovery Today
APRIL 18, 2023
The home of the UK’s lab industry expands floor plan to accommodate increased interest in this year’s show
Chemical Biology and Drug Design
APRIL 19, 2023
This study demonstrates the potential of sclerotiorin isolated from Penicillium mallochii to inhibit acetylcholinesterase. The compound prevents the breakdown of acetylcholine and thereby increases the duration of neurotransmitter in the receptor, eventually helping in improved memory. Abstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder caused due to the damage and loss of neurons in specific brain regions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
APRIL 15, 2023
This chart shows the pharmaceutical companies with the most patents in New Zealand. Patents must be filed in each country (or, in some cases regional patent office) where patent protection… The post Which pharmaceutical companies have the most drug patents in New Zealand? appeared first on DrugPatentWatch - Make Better Decisions.
FDA Law Blog: Biosimilars
APRIL 18, 2023
By Larry K. Houck — In addition to regulating drugs of abuse, the federal Controlled Substances Act (“CSA”) controls the manufacture and distribution of chemicals used in the illicit manufacture of controlled substances. As the primary agency enforcing the CSA, the Drug Enforcement Administration (“DEA”) previously designated nine chemicals used in the illicit manufacture of fentanyl or its analogues as List I or List II chemicals.
Drug Discovery Today
APRIL 21, 2023
Domainex is honoured to announce it has received a King’s Award for Enterprise: International Trade 2023.
Chemical Biology and Drug Design
APRIL 18, 2023
Herein, we report a novel class of NSD3 histone methyltransferase inhibitor. Our inhibitor ( 13i ) was predicted to show showed a unique, bivalent binding mode interacting with both SAM-binding site and BT3-bindig site within the SET domain. Its in vitro activity and cellular activity were validated. Abstract NSD3/WHSC1L1 lysine methyltransferase promotes the transcription of target genes through di- or tri-methylation at histone H3K36 using SAM as a cofactor.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
APRIL 21, 2023
Annual Drug Patent Expirations for NEXLETOL Nexletol is a drug marketed by Esperion Theraps Inc and is included in one NDA. It is available from one supplier. There are six… The post New patent for Esperion Theraps drug NEXLETOL appeared first on DrugPatentWatch - Make Better Decisions.
Crucial Data Solutions
APRIL 21, 2023
How easy to use is your eClinical software for front-end users (participants and site team members) and for back-end users who build and manage the studies? Let's break down the reasons why this is such an important consideration in this blog post. The post One Key to Choosing the Best eClinical Technology Vendor: Great Partners Keep It Simple appeared first on Crucial Data Solutions.
Cytel
APRIL 21, 2023
It was early March 2020, after the world was hit by the Covid-19 pandemic, that those of us on the CDISC Eu committee together with the CDISC team had to make the decision to switch our upcoming CDISC Eu 2020 event from face-to-face to virtual. This was done in less than two months with a very successful outcome, despite the regret of not seeing all our colleagues and friends from all over Europe.
Chemical Biology and Drug Design
APRIL 18, 2023
Protective effects and mechanism of Paecilomyces cicadae TJJ1213 intracellular polysaccharide against H 2 O 2 -induced PC12 cells damage. Abstract Oxidative stress is a key process in the development of neurodegenerative diseases. More attention is needed to screen natural antioxidants and explore pharmacological mechanisms. Natural product polysaccharides with no toxic side effects have powerful antioxidant activity.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
APRIL 21, 2023
Annual Drug Patent Expirations for TAVNEOS Tavneos is a drug marketed by Chemocentryx and is included in one NDA. It is available from one supplier. There are two patents protecting… The post New patent for Chemocentryx drug TAVNEOS appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
APRIL 21, 2023
Today’s guest post comes from Ticia Cawley, VP of Client Solutions at ConnectiveRx. Ticia reviews four interim findings from ConnectiveRx's survey of buy-and-bill prescribers and their support staff. The survey reveals new insights about how practices evaluate automation and digital tools for provider-administered specialty therapies. To learn more, register for ConnectiveRx’s free online panel discussion on May 17th at 1:00 p.m.
Crucial Data Solutions
APRIL 21, 2023
Clinical trials require a ton of people power. Further, many facets of clinical trials call for highly specialized help, whether that be process expertise or the ability to provide technology solutions. Few research sponsors and even CROs have teams in place that address every last need for a given trial. This is not to mention that clinical trials, in general, are becoming more complex every day with data coming from a nearly limitless number of sources and pressure to make trials more inclusiv
Chemical Biology and Drug Design
APRIL 18, 2023
The severity of chagas disease remains a major concern in endemic areas and an emerging public health hazard in nonendemic countries. Trypanosoma cruzi , the etiological agent of this NTD, is mostly transmitted by triatomine vectors and comprises a range of epidemiologically significant variants. Abstract Twenty different infectious disorders induced by bacteria, viruses, and parasites are categorized as neglected tropical diseases (NTDs) by WHO.
Drug Patent Watch
APRIL 21, 2023
Annual Drug Patent Expirations for NEXLIZET Nexlizet is a drug marketed by Esperion Theraps Inc and is included in one NDA. It is available from one supplier. There are seven… The post New patent for Esperion Theraps drug NEXLIZET appeared first on DrugPatentWatch - Make Better Decisions.
PLOS: DNA Science
APRIL 20, 2023
On April 25, 1953, “MOLECULAR STRUCTURE OF NUCLEIC ACIDS: A Structure for Deoxyribose Nucleic Acid” was published in Nature. J. D. Watson and F. H. C. Crick’s work was a brilliant deduction based on the experimental findings of many others. DNA is a sleek double helix, with “rungs” consisting of a purine base paired with a smaller pyrimidine base: adenine (A) with thymine (T) and guanine (G) with cytosine (C).
Labcorp Drug Development
APRIL 20, 2023
There is pressure worldwide for better, faster access to biological alternatives to conventional crop protection chemicals (CPCs). The U.S. Environmental Protection Agency (EPA) is ahead of regions such as the European Union (EU) in revising its regulatory approaches for biopesticides and in having a division dedicated to them, namely, the … The post Faster access to biopesticide alternatives to conventional pesticides under the U.S.
Chemical Biology and Drug Design
APRIL 18, 2023
Role and mechanism of Stat5 in NLRP3-mediated pyroptosis and CR of BC cells. Abstract The treatment of breast cancer (BC) calls for targeted methods to overcome chemoresistance (CR). This study is expected to figure out the mechanism of signal transducer and activator of transcription 5 (STAT5) in NOD-like receptor family pyrin domain containing 3 (NLRP3)-mediated pyroptosis and CR in BC cells.
Drug Patent Watch
APRIL 21, 2023
Annual Drug Patent Expirations for VTAMA Vtama is a drug marketed by Dermavant Sci and is included in one NDA. It is available from one supplier. There are four patents… The post New patent for Dermavant Sci drug VTAMA appeared first on DrugPatentWatch - Make Better Decisions.
Antidote
APRIL 20, 2023
When contract research organizations and pharmaceutical sponsors need to recruit patients for clinical trials, they often work with clinical trial marketing and advertising companies to reach the right candidates. These companies use strategies like digital outreach, partnering with patient advocacy organizations, and other tactics to reach patients who may qualify for a trial and inform them on how to enroll.
Crucial Data Solutions
APRIL 19, 2023
Does your eClinical provider offer the scalability and extensibility you need to best support your trials over time? Keep reading for our interpretation of why this should be taken into consideration when selecting a technology partner. The post The Importance of Flexibility in an eClinical Technology Partner appeared first on Crucial Data Solutions.
Chemical Biology and Drug Design
APRIL 16, 2023
A decline in angiogenesis becomes pronounced with increasing age and related to the abnormal function of endothelial cells. Nitric oxide (NO) can counteract endothelial cell senescence and NO donor-based senescent cell scavengers and SASP inhibitors promote angiogenesis. Abstract The decrease in angiogenesis that occurs with aging significantly contributes to the higher incidence and mortality of cardiovascular diseases among the elderly.
Drug Patent Watch
APRIL 20, 2023
Annual Drug Patent Expirations for TESTIM Testim is a drug marketed by Auxilium Pharms Llc and is included in one NDA. It is available from one supplier. There are ten… The post New patent expiration for Auxilium Pharms drug TESTIM appeared first on DrugPatentWatch - Make Better Decisions.
keypoint
APRIL 19, 2023
Over the course of the last 50 years, Keystone Symposia has convened conferences that connect scientists within and across disciplines to solve the greatest challenges in biomedical and life sciences, from HIV to cancer to emerging pandemic threats.
New Drug Approvals
APRIL 18, 2023
MAVORIXAFOR AMD 070 N1-(1H-BENZIMIDAZOL-2-YLMETHYL)-N1-((S)-5,6,7,8-TETRAHYDROQUINOLIN-8-YL)-BUTANE-1,4-DIAMINE Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC 50 value of 13 nM against CXCR4 125 I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC 50 of 1 and 9 nM, respectively.
Expert insights. Personalized for you.
130 
Let's personalize your content